Sino Biopharmaceutical

Asia
Pharma

Kyowa, Sino Biopharm, Duality—Fierce Pharma Asia

Kyowa Kirin ended its autoimmune program after new cancer reports. Sanofi linked up with Sino Biopharm. BioNTech advanced a DualityBio ADC. And more.
Angus Liu Mar 6, 2026 9:35am
Sanofi

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am
newspaper

Pfizer-Fosun, Zealand, China's new formulary—Fierce Pharma Asia

Dec 12, 2025 8:15am
newspaper

China biotech deals, Takeda, LaNova—Fierce Pharma Asia

Jul 18, 2025 9:04am
Stamp with blue ink that says FDA Approved

Akeso’s Anniko enters crowded US PD-1 market

Apr 25, 2025 10:55am
Asia

Geopolitical tensions, Carvykti, Enhertu—Fierce Pharma Asia

Apr 12, 2024 8:20am